Brunini Tmc, Moss Mb, Siqueira Mas, Meirelles Lr, Rozentul Al, Mann Ge, Ellory Jc, Soares de Moura R, Mendes-Ribeiro Ac
Departamento de Farmacologia e Psicobiologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Clin Exp Pharmacol Physiol. 2004 Oct;31(10):738-40. doi: 10.1111/j.1440-1681.2004.04067.x.
Nitric oxide (NO) produced by human platelets plays an important role in all stages of platelet activation. l-Arginine, the precursor for NO synthesis, modulates NO production by platelets. The l-arginine analogues asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-l-arginine (l-NMMA) are endogenous inhibitors of nitric oxide synthase (NOS), involved in the physiopathology of arterial hypertension. The aim of the present study was to investigate the inhibitory effects of endogenous and exogenous l-arginine analogues on l-arginine influx in platelets from healthy controls and hypertensive patients. Twelve patients with uncomplicated essential hypertension (stage I) and 15 age-matched normotensive controls participated in the present study. Platelets were isolated and incubated with l-[(3)H]-arginine and increasing concentrations of l-arginine analogues (5-2000 micromol/L). The influx of l-arginine was inhibited in a concentration-dependent manner by l-NMMA in platelets from controls (K(i) = 42 +/- 6 micromol/L) and this inhibitory effect was markedly higher in hypertensive platelets (K(i) = 23 +/- 4 micromol/L). Similarly, the K(i) for ADMA inhibition of l-arginine transport was significantly more pronounced in platelets from hypertensive patients (K(i) = 16 +/- 1 micromol/L) compared with controls (K(i) = 27 +/- 2 micromol/L). In contrast, N(G)-nitro-l-arginine methyl ester (l-NAME) was found to be a weak inhibitor of l-arginine influx in platelets from controls (K(i) = 1917 +/- 319 micromol/L) and hypertensive patients (K(i) = 2279 +/- 578 micromol/L). Aminoguanidine, a selective inhibitor of inducible NOS, failed to inhibit l-arginine transport. Our findings provide the first evidence that ADMA and l-NMMA markedly inhibit l-arginine transport in human platelets, an effect that is more pronounced in hypertensive patients. It is possible that endogenous l-arginine analogues, by inhibiting NO synthesis, are involved in the platelet activation present in hypertension.
人血小板产生的一氧化氮(NO)在血小板激活的各个阶段都发挥着重要作用。L-精氨酸作为NO合成的前体,可调节血小板的NO生成。L-精氨酸类似物不对称二甲基精氨酸(ADMA)和N(G)-单甲基-L-精氨酸(L-NMMA)是一氧化氮合酶(NOS)的内源性抑制剂,与动脉高血压的病理生理过程有关。本研究的目的是探讨内源性和外源性L-精氨酸类似物对健康对照者和高血压患者血小板中L-精氨酸内流的抑制作用。12例无并发症的原发性高血压患者(I期)和15例年龄匹配的血压正常对照者参与了本研究。分离血小板并与L-[(3)H]-精氨酸和浓度不断增加的L-精氨酸类似物(5-2000 μmol/L)一起孵育。L-NMMA以浓度依赖性方式抑制对照者血小板中L-精氨酸的内流(K(i)=42±6 μmol/L),且这种抑制作用在高血压患者的血小板中更为明显(K(i)=23±4 μmol/L)。同样,与对照者(K(i)=27±2 μmol/L)相比,ADMA对L-精氨酸转运的抑制作用在高血压患者血小板中更为显著(K(i)=16±1 μmol/L)。相反,发现N(G)-硝基-L-精氨酸甲酯(L-NAME)是对照者血小板(K(i)=1917±319 μmol/L)和高血压患者血小板(K(i)=2279±578 μmol/L)中L-精氨酸内流的弱抑制剂。氨基胍作为诱导型NOS的选择性抑制剂,未能抑制L-精氨酸的转运。我们的研究结果首次证明,ADMA和L-NMMA可显著抑制人血小板中L-精氨酸的转运,且这种作用在高血压患者中更为明显。内源性L-精氨酸类似物可能通过抑制NO合成而参与高血压患者中存在的血小板激活过程。